国产重组链激酶治疗急性心肌梗死临床观察  

The Clinical Trial of China-Made Recombinant Streptokinase(r-sk) in Acute Myocardial Inearction

作　　者：樊世明[1] 柳茵[1] 李琳[1] 刘维军[1] 于伊[1] 梅峰[1] 刘连军[1] 王红[1] 严鹏仲[1] 任明[1] 马艳梅[1] 

机构地区：[1]青海医学院附属医院心内科,810001

出　　处：《青海医药杂志》2004年第7期4-5,共2页Qinghai Medical Journal

摘　　要：目的 :观察国产重组链激酶 (r -sk)对急性心肌梗死 (AMI)静脉溶栓的治疗和不良反应 ,对其安全性和疗效做出评价。方法 :所有病例均符合入选和不入选标准 ,予r -sk 15 0万单位于 6 0分钟内静滴 ,观察血管再通的临床指标及不良反应。结果 :6 4例患者血管再通率为 82 .8% ,出血发生率为 9.38% ,表现为胃肠道轻微出血 ,未经特殊处理自行消失。结论 :r -sk静脉溶栓再通率高 ,不良反应少 ,为一安全有效的溶栓剂。Objective: The purpose of this study is to evaluate the efficacy and safety of intravenous recombinant streptokinase(r-sk), produced in China, in the treatment of acute myocardial infarction(AMI). Methods: 1.5million units of r-sk were given intravenously over 60 minutes and the clinical criteria of reperfusion were evaluated. Results: The reperfusion rate for r-sk was 82.8%, mild bleeding occurred respectively in 9.38% of patients with r-sk. Conclusion: China-made r-sk is a safe and effective thrombolytic agent.

关 键 词：治疗 重组链激酶 不良反应 血管再通 静脉溶栓 急性心肌梗死 观察 国产 目的 单位 

分 类 号：R542[医药卫生—心血管疾病] R735.7[医药卫生—内科学]